S U M M A R Y S E T T I N G :
The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence.
O B J E C T I V E :
To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati.
M E T H O D S :
We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. R E S U LT S : Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of 790%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. C O N C L U S I O N : Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations. K E Y W O R D S : mass treatment; tuberculosis; elimination THE ELIMINATION of tuberculosis (TB) at the global level by 2050 is an internationally agreed target. 1 Elimination has been defined as an annual incidence rate of ,1 new TB case per 1 000 000 population, a rate expected to prevent sustained transmission of Mycobacterium tuberculosis. 2, 3 However, TB elimination is clearly unrealistic without new tools and approaches. 4 One thing is clear: a combined, simultaneous attack on active disease and latent tuberculous infection (LTBI) will be necessary. 2, 4 Active case finding plus mass prophylactic treatment against LTBI was evaluated by Comstock et It is important to ask why active case finding plus mass prophylactic treatment was so unsuccessful with respect to TB elimination. One strong possibility is that individuals with active TB disease were initially missed due to limitations in diagnostic procedures. An alternative mass treatment strategy that may overcome this limitation is the administration of a treatment regimen for TB disease to the whole population.
We aimed to assess whether such a strategy could lead to TB elimination in the well-defined, isolated population of Kiribati in the Pacific, where mass prophylactic treatment for leprosy has been undertaken previously with high rates of community participation. 9 
METHODS

Strategy and rationale
In this approach, a full course of anti-tuberculosis treatment is given to everyone: those with active disease (diagnosed and undiagnosed), those with LTBI and those who are not infected with M. tuberculosis. The rationale is as follows: all those with active, drug-susceptible disease will be treated and rendered non-infectious rapidly, those with drugsusceptible LTBI will have all residual tubercle bacilli killed, and those without infection will be prevented from getting infected at least while on treatment.
Setting
The Republic of Kiribati comprises 35 atolls and one raised coral island spread across 3.5 million km 2 in the central tropical Pacific. Almost half of the population of approximately 100 000 people lives in one urban area, South Tarawa. Kiribati is one of the poorest and least developed countries in the Pacific and is heavily reliant on external sources of income. It has a TB epidemic, with an annual case notification rate of approximately 335 new TB cases/100 000/ year since the mid-1990s ( Figure 1A ). Kiribati has a young population ( Figure 1B) , and the age group 15-24 years has the largest number of cases ( Figure 1C) . The equally high rates of TB incidence among adults of all ages are indicative of ongoing transmission ( Figure 1D ). In a recent (2011) survey of a representative sample of 394 adults (aged .18 years), 45% were tuberculin skin test positive, with a peak of 66% in those aged 45-54 years (unpublished data). The rate of increase in the percentage positive by age suggests an average annual risk of infection of about As this study used routinely available data, ethical permission was not required.
Model
To determine the effects of mass treatment in Kiribati, we constructed a compartmental model of the life cycle of M. tuberculosis in which active TB disease, both infectious and non-infectious, arises from the progression of infection, reinfection, reactivation and relapse. 4 Figure 2 shows the seven exclusive states included in the closed model (no migration). The corresponding set of coupled non-linear difference equations and model parameter values based on previous similar analyses 4 are shown in the Appendix.* Using the solver function in Microsoft Excel (Microsoft, Redmond, WA, USA), we fitted the model to the series of annual case reports from Kiribati ( Figure 1A ) by varying the contact rate b, assuming that TB was stably endemic before any further intervention, at an average of 330 cases/ 100 000 reported between 2000 and 2012. With the point estimates given in Appendix Table A, the basic case reproduction number of TB in Kiribati is R 0 ¼ 4.3 and the annual risk of infection in the steady state is approximately 3%.
To improve the effective treatment of active disease, we increased the rate of transfer of infectious and non-infectious TB cases to the cured state. The rate of transfer is determined by the product of the case detection rate and the proportion cured. Cases who are detected but not cured remain cases of active disease. To represent periodic rounds of mass treatment of the population in the model, a proportion p of people (0.6, 0.8, 0.9 or 0.95) in each of the classes Lf and Ls are moved instantly, at 5-year intervals, to 'treated latent' class C l . At the same time, a proportion p of I and N are moved to 'cured' class C d , with a chance of relapse back to I and N. To replicate the protective effect of treating non-infected people, U, the contact rate b between I and U was scaled down to b(1Àr) for the 6-month duration of treatment, after which it reverts to b. Control variable p, our measure of effectiveness, is the product of population coverage and treatment efficacy per capita.
To investigate the factors responsible for uncertainty in outcomes, we generated 1000 Latin hypercube samples with a Mersenne twister (Palisade @Risk software; Palisade Corp, Ithaca, NY, USA) along a uniform distribution between low and high parameter values (Appendix Table A ). The importance of each model parameter was measured by the correlation between values of that parameter and values of the primary outcome measure, the TB incidence rate in 2050.
RESULTS
Routine TB control TB control as currently practised by the NTP is represented by a detection rate of cases I and N of 0.4/ year, so that the proportion of cases ever detected is 0.58, with the proportion of cases cured set at 0.8. Under these circumstances, the average duration of an infectious TB case is 1.5 years. To illustrate an improvement in routine TB control, the case detection rate is increased to 1.9/year (0.96 of all cases ever detected) and the proportion cured increased to 0.85. This reduces the average duration of an infectious case threefold, from 1.5 years to 0.5 years. This has the effect of forcing down the TB incidence rate at an average of 10% per year over the 10 years from 2015 to 2024, to around 100/100 000 population by 2035 ( Figure 3, line 3) . To reduce the incidence by a factor of three in 20 years is significant progress. However, it is clear that no level of improvement to routine TB Mass anti-tuberculosis treatment control could eliminate TB in Kiribati within the space of a few decades. An alternative way to reduce incidence is by mass periodic treatment of active TB. However, a strategy of curing 0.9 of all TB cases every 5 years would be less successful than improving routine control in the example above ( Figure 3 , compare lines 2 and 3).
Periodic mass treatment of the whole population
In the calculations illustrated in Figure 3 , we explored the effects of r ¼ 0.6, 0.8, 0.9 and 0.95. With a treatment effectiveness of r ¼ 0.9 for LTBI and active TB, and the same proportion of non-infected people protected against infection, the annual TB incidence is expected to drop precipitously at each 5-yearly round of treatment, falling to the elimination threshold within two decades (by 2035, Figure 3 , line 5). Improving treatment effectiveness to 0.95 would lead to elimination by 2030. The lowest possible incidence rate to which lines converge is governed by the incidence of relapse after successful treatment of active TB.
Uncertainty analysis
The results of the sensitivity analysis of TB incidence rate in 2050 to each of the model parameters, where sensitivity is measured by the correlation coefficient, are presented in Appendix Figure A . The relapse rate after treatment of active TB is by far the most important determinant of TB incidence rate in 2050. With a per capita relapse rate higher than 10 À5 per year, it would not be possible to eliminate TB by 2050. However, irrespective of whether or not the elimination threshold is reached, the analysis is robust to our main conclusion: periodic mass treatment is a far more effective way of reducing TB incidence than the routine treatment of active disease.
DISCUSSION
In this paper, we have used mathematical modelling to investigate whether mass treatment with a full course of anti-tuberculosis drugs could eliminate TB from what might be considered an ideal target population -a Pacific island nation with a poorly controlled TB epidemic. Assuming a high level of mass treatment effectiveness for LTBI and active TB (r 7 0.9) and protection of non-infected people, the annual TB incidence is expected to fall precipitously at each 5-yearly round of treatment, approaching elimination in two decades.
We have obtained this result with a simple compartmental model of TB epidemiology. We do not therefore claim to make precise forecasts of when elimination could be achieved in Kiribati. For example, the lowest achievable incidence rate within the next few decades is sensitive to the relapse rate after treatment of active TB, which is not accurately known. It is exposed by this study as a crucial factor in TB elimination. The uncertainty surrounding these details does not detract from the key point of our analysis, which is that mass population treatment is a far more effective intervention than routine treatment of active TB. We do not propose that the former should replace the latter, but rather that mass treatment would be a powerful supplementary measure to cut TB incidence to a minimum within 2-3 decades.
A number of issues require careful consideration (Table) beyond a formal cost analysis, which is outside of the scope of this paper. First, shorter regimens could be considered. Those with LTBI are likely to be successfully treated after 3 months of a regimen that includes both RMP and INH. 10 While relapse rates are lowest with 6 months of treatment, they are almost as low with regimens as short as 3 months' duration. 11 Indeed, studies could address whether those with occult, asymptomatic disease could be safely treated with less than 6 months of treatment. It is also anticipated that new drug regimens for all TB disease will be shorter in the future and have fewer side effects. 12 Second, the main concern with respect to the side effects of treatment is hepatotoxicity. Interpretation of the available data is complicated by a disconnect between biochemical indices and clinical manifestations of hepatotoxicity, 13 the lack of a standardised approach to diagnosis and management, and huge variations in the reported risk. 14 Reassuringly, a study of 752 Danish patients on anti-tuberculosis treatment showed that the drugs could be continued, or successfully reintroduced in full, in most patients in whom liver enzyme levels increased up to six times the upper limit of normal. 15 Additional reassurance is provided from resource-poor countries, where the bulk of anti-tuberculosis treatment is provided without routine biochemical testing -there have not been large numbers of reported cases of fatal drug-induced hepatitis.
Third, consideration could be given to excluding certain groups from treatment. In their trial, Comstock et al. excluded children aged ,2 months who had no known TB contact. 5 Other groups that could also be considered for exclusion are shown in the Table. Fourth, a comprehensive public health approach would be required. Standardised surveillance of active disease would be necessary before and after the intervention, and appropriate processes would be required for dealing with data. The project would also require public education and engagement, adequate finances and staff, overall project management, and reliable and timely monitoring, evaluation and reporting. Elimination from an island would only be theoretically possible if, after the whole population has received treatment, they are no longer exposed to M. tuberculosis. Those persons who travel back and forth to the islands (e.g., for trade, education, etc.) and new immigrants would therefore need to be considered for treatment.
Fifth, there are important ethical principles to consider with any mass treatment strategy. 16 Major issues include how to weigh population benefit against the lack of guaranteed benefit to any single individual and the potential to cause harm, how to engage in a sustained manner with the community and how to avoid coercion, which can be difficult to differentiate from persuasion in the context of a public health promotion and education campaign required for the project.
Mass treatment of the population for TB would have other non-TB benefits. For example, RMP is an effective prophylactic agent against leprosy, which remains endemic in many Pacific countries, presumably through clearance of nasal carriage. 17 As mentioned above, mass prophylactic treatment for leprosy was undertaken in Kiribati in the 1990s, with very high rates of community participation of over 90%. 9 Providing anti-tuberculosis treatment to the whole population could in theory eliminate TB in an island nation such as Kiribati, without any other public health actions and without improved diagnostic tests. Sub-total coverage and the potential for future relapse with current anti-tuberculosis treatment implies that more than one round of treatment is required. While there are a number of issues that need to be considered, this approach is likely to become more feasible with the availability of more effective, shorter and safer drug regimens. In anticipation of this, a number of preliminary studies could be conducted specifically to facilitate such an approach. A Pacific Island nation such as Kiribati has great potential to host preparatory studies with a view to a mass treatment approach in the future. Components of the project A project management plan is required including finances, procurement and distribution, recruitment and training of staff, communication, education, health promotion, protocols, information systems, roll out, evaluation and supervision New policies may need to be introduced e.g., border control
Mass anti-tuberculosis treatment
APPENDIX
The different equations describing the dynamics of the seven health states in Figure 1 are as follows. The notation implies, for uninfected people, that U tþ1 ¼ f(U t , I t , N t ), etc., for each of the seven states. The subscripts denoting time (t, tþ1) are dropped for clarity. Definitions of parameters are shown in Table  A . This compartmental model describes the baseline epidemiology of TB, before introducing the further interventions described in the main text.
Uninfected (U)
Active TB treated with drugs (C d )
The final state, consisting of people with latent tuberculous infection who have been successfully treated (C l ), is created only by periodic mass treatment of L f and L s , as described in the main text.
The rate of loss from this compartment is
The basic case reproduction number of this system is as follows:
where c is the average number of episodes of infectious TB suffered by each case, allowing for relapse from natural cure and from cure following drug treatment. The proportion of infectious cases that goes through one cycle of cure and relapse is:
Therefore, the total number of cycles or episodes is c ¼ 1/(1 À c). Table A ), where sensitivity is measured by the correlation coefficient. En estimantà 790% l'efficacité du traitement de toute une population pour une infection tuberculeuse latente et une TB active, l'incidence annuelle de la TB devrait chuter brutalement lors de chaque traitement de masse tous les 5 ans, arrivantà l'élimination en deux décennies. Le modèle a montré que l'incidenceétait sensibleà la rechute après un traitement réussi de la TB. C O N C L U S I O N : Le traitement de masse pourrait contribueràéliminer la TB, au moins dans des populations distinctes ou géographiquement isolées.
R E S U M E N M A R C O D E R E F E R E N C I A:
La meta mundial de eliminación de la tuberculosis (TB) en el 2050 exige nuevos enfoques. Los resultados de la búsqueda activa de casos aunada al tratamiento profilá ctico colectivo han sido decepcionantes. Se propone el tratamiento antituberculoso completo colectivo como estrategia de eliminación en Kiribati, una isla del Pacífico con una epidemia de TB persistente de alta incidencia. O B J E T I V O: Construir un modelo matemá tico que permitiese predecir si un plan colectivo de tratamiento antituberculoso completo podría eliminar la TB en una población definida de la república de Kiribati.
M É T O D O S:
Se construyó un modelo compartimental de siete estados clínicos de la infección por Mycobacterium tuberculosis, en el cual la enfermedad activa surge de la progresión de la infección, la reinfección, la reactivación o la recaída, distinguiendo la enfermedad contagiosa de la enfermedad no contagiosa. Mediante un aná lisis de incertidumbre se evaluaron los efectos de 5 años de tratamiento colectivo, al aplicar una serie de pará metros con el fin de generar desenlaces clínicos. R E S U LTA D O S: En la hipótesis de que la eficacia de un tratamiento a escala poblacional de la infección tuberculosa latente y de la enfermedad activa es 790%, se prevé que la incidencia anual de TB disminuya de manera pronunciada en cada ronda de 5 años de tratamiento y se llegue cerca de la eliminación en dos decenios de aplicación. El modelo puso en evidencia que la tasa de incidencia es sensible a la tasa de recaída después de un tratamiento antituberculoso eficaz. C O N C L U S I Ó N: El tratamiento colectivo podría contribuir a eliminar la TB, por lo menos en poblaciones definidas o geográ ficamente aisladas.
